Bristol's drug cocktail cuts kidney cancer death risk 37 percent

Bristol's drug cocktail cuts kidney cancer death risk 37 percentBy Ben Hirschler MADRID (Reuters) - A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday. In August, Bristol-Myers reported Opdivo and Yervoy failed to significantly outperform standard care in checking cancer progression, although there was a trend toward benefit.